Literature DB >> 24085542

Proteomic analysis of meningiomas.

G Q Cui1, A H Jiao, C M Xiu, Y B Wang, P Sun, L M Zhang, X G Li.   

Abstract

Meningiomas represent one-third of all primary brain tumors and cause 35,000 new cases each year. Because of this high incidence, we sought to determine if there are proteomic differences between meningiomas and neighboring tissues. Two-dimensional gel electrophoresis and mass spectrometry were used to detect differentially expressed proteins in tumor samples, using arachnoid tissue as a control. Western blot analysis was used to validate the identified candidate proteins. We obtained quantitative data on 112 proteins, 17 of which were down-regulated and 26 of which were up-regulated in meningiomas relative to normal arachnoid tissue. Our analysis showed that the expression of galectin-3, vimentin, and endoplasmin was decreased significantly in meningiomas. The expression of 40S ribosomal protein S12, glutathione S-transferase P, and hypoxia up-regulated protein 1 was increased significantly (P < 0.05). The six above-mentioned differentially expressed proteins might be closely involved with the development of meningiomas. The results of this study provide basic insights into the proteome of meningiomas and provide a preliminary database for further research to enhance understanding of meningioma development.

Entities:  

Mesh:

Year:  2013        PMID: 24085542     DOI: 10.1007/s13760-013-0253-z

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  8 in total

1.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 2.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

3.  Evaluation of autoantibody signatures in meningioma patients using human proteome arrays.

Authors:  Shabarni Gupta; Shuvolina Mukherjee; Parvez Syed; Narendra Goud Pandala; Saket Choudhary; Vedita Anand Singh; Namrata Singh; Heng Zhu; Sridhar Epari; Santosh B Noronha; Aliasgar Moiyadi; Sanjeeva Srivastava
Journal:  Oncotarget       Date:  2017-04-10

4.  Proteomics pinpoints alterations in grade I meningiomas of male versus female patients.

Authors:  Janaína M Silva; Helisa H Wippel; Marlon D M Santos; Denildo C A Verissimo; Renata M Santos; Fábio C S Nogueira; Gustavo A R Passos; Sergio L Sprengel; Luis A B Borba; Paulo C Carvalho; Juliana de S da G Fischer
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

Review 5.  Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy.

Authors:  Rashmi Rana; Swati Sharma; Nirmal Kumar Ganguly
Journal:  Mol Biol Rep       Date:  2021-10-23       Impact factor: 2.316

Review 6.  Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.

Authors:  Hajime Takase; Tetsuya Yamamoto
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

7.  Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression.

Authors:  Carolina Angelica Parada; Joshua Osbun; Sumanpreet Kaur; Youssef Yakkioui; Min Shi; Catherine Pan; Tina Busald; Yigit Karasozen; Luis Francisco Gonzalez-Cuyar; Robert Rostomily; Jing Zhang; Manuel Ferreira
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

Review 8.  Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis.

Authors:  Jiachen Liu; Congcong Xia; Gaiqing Wang
Journal:  Front Oncol       Date:  2020-08-28       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.